Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,331 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | not yet recruiting | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07835737 | Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 78 | West China HospitalOTHER | 0 | Sep 23, 2026 |
| clinicaltrials |
| NCT07540832 | A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC | not yet recruiting | Phase 1 / Phase 2 | 80 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07632235 | A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai 6th People's HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07551778 | Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 42 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07761286 | Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 288 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07714317 | Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet) | not yet recruiting | Phase 1 / Phase 2 | 90 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 20, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07691450 | Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma | not yet recruiting | Phase 1 | 40 | City of Hope Medical CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07587034 | HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer | not yet recruiting | Phase 1 / Phase 2 | 315 | Shanghai Zhongshan HospitalOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07590336 | 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma(NYHCC) | not yet recruiting | Phase 1 / Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07583316 | A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors | not yet recruiting | Phase 1 | 192 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07580261 | YMN-A02 for Advanced Primary Hepatocellular Carcinoma. | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07558200 | Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors | not yet recruiting | Phase 1 | 138 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07522411 | Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 100 | BinYong LiangOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07282509 | Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer | not yet recruiting | Phase 1 / Phase 2 | 116 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07260058 | Immune Cell Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 48 | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.INDUSTRY | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT06400160 | Clinical Trial of TB511 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | Twinpig Biolab, Inc.INDUSTRY | 0 | Nov 25, 2025 | clinicaltrials |
| NCT07224568 | Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors(INTERCEPT) | not yet recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT07187284 | EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial | not yet recruiting | Phase 1 / Phase 2 | 62 | Zhongda HospitalOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07077369 | WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 0 | Jul 22, 2025 | clinicaltrials |
| NCT07075419 | JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure | not yet recruiting | Phase 1 / Phase 2 | 10 | West China HospitalOTHER | 0 | Jul 20, 2025 | clinicaltrials |
| NCT06994572 | Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 1 | 141 | Captor Therapeutics S.A.INDUSTRY | 0 | May 29, 2025 | clinicaltrials |
| NCT06990620 | TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC(TACE HCC) | not yet recruiting | Phase 1 | 56 | Fudan UniversityOTHER | 0 | May 25, 2025 | clinicaltrials |
| NCT06896396 | Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 60 | Zhiyong HuangOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06822985 | QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma(QL1706) | not yet recruiting | Phase 1 | 21 | Wan-Guang ZhangOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06584071 | A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC | not yet recruiting | Phase 1 / Phase 2 | 140 | Biotheus Inc.INDUSTRY | 0 | Dec 16, 2024 | clinicaltrials |
| NCT06641453 | CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06409637 | FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation | not yet recruiting | Phase 1 / Phase 2 | 62 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06364787 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma | not yet recruiting | Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT05286320 | Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. | not yet recruiting | Phase 1 / Phase 2 | 27 | National Taiwan University HospitalOTHER | 1 | Mar 2, 2023 | clinicaltrials |
Data updated 14 hours agoSource updated Sep 29, 2026source: clinicaltrials